公开(公告)号：US12145941B2

公开(公告)日：2024-11-19

申请号：US18075557

申请日：2022-12-06

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Joseph D. Panarese ,  Sean Rafferty ,  Jonathan Thielman ,  Nathaniel T. Kenton ,  Samuel Bartlett ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14 ,  C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240140922A1

公开(公告)日：2024-05-02

申请号：US18236560

申请日：2023-08-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Samuel Bartlett ,  Joseph D. Panarese ,  Sourav Ghorai ,  Nathaniel Thomas Kenton ,  Sean Rafferty ,  Jonathan Thielman ,  Peilin Xu ,  Bin Wang ,  William Cassels ,  Scott Mitchell ,  Yat Sun Or

IPC: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

CPC classification number: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230174542A1

公开(公告)日：2023-06-08

申请号：US18075557

申请日：2022-12-06

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Joseph D. Panarese ,  Sean Rafferty ,  Jonathan Thielman ,  Nathaniel T. Kenton ,  Samuel Bartlett ,  Yat Sun Or

IPC: C07D487/10 ,  C07D519/00 ,  A61P31/14

CPC classification number: C07D487/10 ,  C07D519/00 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.